JPMorgan upgrades Martin Marietta stock, sees 14% EBITDA growth in 2025

EditorEmilio Ghigini
Published 27/11/2024, 06:38 pm
MLM
-

On Wednesday, JPMorgan (NYSE:JPM) made a notable adjustment to its stance on Martin Marietta Materials (NYSE:MLM), upgrading the stock from Neutral to Overweight and raising the price target to $640 from the previous $515. According to the firm's analysis, Martin Marietta's EBITDA for the current year is projected to be down 4% year-over-year, but still aligns closely with the company's own guidance range of $2.015 to $2.115 billion.

For the fiscal year 2025, JPMorgan has increased its estimates by 4%, anticipating a 14% year-over-year growth in EBITDA, buoyed by a 1.2 percentage point margin expansion to 32.7%. This outlook is based on an expected 10% year-over-year increase in top-line revenue, factoring in a 4% rise in aggregate volumes and a 7% increase in prices. The firm notes that Martin Marietta has been slightly more aggressive in its pricing compared to its peers, which might mean there are lower risks of prices rising above expectations.

JPMorgan's revised price target of $640 signifies a 7% upside from the current level. This new target is based on a forward EV/EBITDA multiple of 16.5 times, which is above the standard deviation compared to the average. The firm highlighted that Martin Marietta is currently trading at a multiple of 17 times.

The upgrade and new price target reflect JPMorgan's positive outlook on Martin Marietta Materials' financial performance and market position in the coming years. The firm's analysis suggests confidence in the company's ability to expand margins and grow its business amid industry pricing dynamics.

In other recent news, Martin Marietta Materials has exhibited robust financial performance despite weather-related disruptions. The company achieved a record quarterly aggregates gross profit per ton of $8.16 and a 32% increase in cash flows from operations, totaling $601 million. However, these weather events led to a revised full-year adjusted EBITDA guidance of $2.07 billion. In financial maneuvers, Martin Marietta issued $1.5 billion in senior unsecured notes, intended to repay outstanding borrowings and allocate for general corporate uses.

Analysts from UBS, Loop Capital, and Stephens have expressed optimism about the company's growth trajectory. UBS initiated coverage on Martin Marietta with a Buy rating, citing strong pricing, cost control, and the potential for mergers and acquisitions. Loop Capital and Stephens maintained positive ratings and increased their price targets to $680 and $675 respectively.

Recent acquisitions in South Florida and California are anticipated to enhance aggregate reserves and margins, with new pricing effective starting January 1, 2025. The company has also returned $591 million to shareholders through dividends and share repurchases. These recent developments highlight Martin Marietta's strategic initiatives and its ability to navigate through challenges.

InvestingPro Insights

Adding to JPMorgan's bullish outlook on Martin Marietta Materials (NYSE:MLM), recent data from InvestingPro provides further context to the company's financial position and market performance. The stock's current P/E ratio of 18.5 aligns with JPMorgan's assessment of MLM trading at a multiple of 17 times. Moreover, MLM's strong return over the last three months, with a 15.29% price total return, supports the positive momentum noted in the analysis.

InvestingPro Tips highlight that MLM has maintained dividend payments for 31 consecutive years and has raised its dividend for 9 consecutive years, indicating a commitment to shareholder returns. This is particularly relevant given JPMorgan's focus on the company's financial performance and growth prospects. Additionally, the tip that MLM is trading near its 52-week high corroborates the stock's recent performance and JPMorgan's upgraded price target.

For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for MLM, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.